ADC & Antibody-Drug Conjugates
ADCs (Antibody-Drug Conjugates) linking antibodies with cytotoxic drugs have emerged as the core of next-gen cancer treatment. Daiichi Sankyo's Enhertu pioneered the market, and big pharma (Merck, AbbVie, Gilead) are investing trillions in acquiring ADC pipelines. Alteogen's subcutaneous injection platform (ALT-B4) is gaining attention as an ADC delivery innovation.
Updated: 2/25/202612-24 months
Investment Confidence
Confidence Index82%
LowMediumHigh
Theme Analysis
Key Drivers
- ADC market growing 25%+ annually ($30B projected by 2030)
- Big pharma expanding ADC pipeline M&A
- Daiichi Sankyo Enhertu indication expansion
- Alteogen ALT-B4 subcutaneous platform licensing expansion
Risk Factors
- ADC clinical failure risk (toxicity/efficacy)
- Pipeline overcrowding
- CMC issues from complex manufacturing processes
- Payer resistance to high drug prices
Catalysts
- Alteogen major licensing deal announcement
- ADC pipeline positive Phase 3 results
- Big pharma ADC company acquisitions
Related Investment Ideas
1Related Reports
1Comments
Created: 2/25/2026Updated: 2/25/2026